Advertisement

Curious2018 pp 47-68 | Cite as

The Changing Landscape for New Drug Development: Medical Countermeasures (MCMs) as a Case Study

  • Christopher-Paul MilneEmail author
Chapter

Abstract

This chapter is comprised of materials adapted from previous publications authored by the Center for the Study of Drug Development at Tufts University School of Medicine (Tufts CSDD) over a ten-year period from 2010 through 2019. In addition, there are occasional infusions of updated commentary to “connect the dots” of how we got to where we are today. These publications may be requested from Tufts CSDD (if originally published in-house) or through the usual channels for requesting articles published in the public domain (permission to reprint the articles having been granted, where required). The text of the chapter is structured basically in a chronological fashion beginning with Tufts CSDD analysis of the early era of MCM evolution as a sub-sector from various extant therapeutic areas. It then chronicles the changes to the R&D paradigm in response to the challenges that emerged for both MCMs and biopharma in general. Finally, it ends with an exploration of the devolution of the MCM sub-sector back into its roots in the infectious disease area as an increase in actual outbreaks as well as other signals of global vulnerability to pandemic threats have minimized the MCM emphasis on biodefense against a wide range of CBRN agents in favor of public health tactics to address humankind’s maladaptation to a world in which it is constantly assailed by its microbial competitors and symbionts, or to novel public health crises of its own making.

References

  1. 1.
    Whalen J. Hurdles multiply for latest drugs. Wall Street J 1 August 2011.Google Scholar
  2. 2.
    Deloitte Consulting, 2018 report, “Unlocking R&D Productivity: Measuring the return from pharmaceutical innovation 2018,” available at www2.deloitte.com. Last accessed 6 Jan 2019.
  3. 3.
    U.S. Centers for Medicare & Medicaid (CMS) report, National Health Expenditures 2017 (Highlights), available at www.cms.gov. Last accessed 6 Jan 2019.
  4. 4.
    Milne, C.-P. Is there a business in medical countermeasures for bioterror and pandemics? (White Paper, 2010). Tufts Center for the Study of Drug Development (Tufts CSDD); Boston, MA, USA.Google Scholar
  5. 5.
  6. 6.
    Industry Experts Fall 2018, Global Influenza Market—Vaccines and Therapeutics (Report Code PH015) at industry-experts.com. Last accessed January 6, 2019.Google Scholar
  7. 7.
    Milne C-P Clinical Pharmacology & Therapeutics 2013;95(1):98–109 advance online publication 30 October 2013.  https://doi.org/10.1038/clpt.2013.155.CrossRefGoogle Scholar
  8. 8.
    Lamberti MJ, Awatin J. Mapping the landscape of patient-centric activities within clinical research. Clin Ther 39(11):2196–2202.  https://doi.org/10.1016/j.clinthera.2017.09.010. Epub 2017 Oct 9. https://www.ncbi.nlm.nih.gov/pubmed/29032849. Last accessed 26 Nov 2018.CrossRefGoogle Scholar
  9. 9.
    Milne C-P, Smith ZP, Chakravarthy R. Landscape for medical countermeasure development. Nat Rev Drug Devel 2017; 16:448–449.CrossRefGoogle Scholar
  10. 10.
    Milne C-P. Reaching a New Innovation Threshold. Pharma Focus Asia (editorial), Ochre Media Pvt. Ltd., Issue 30, 2018. Available at https://www.pharmafocusasia.com/archives-magazine/81. Last accessed 26 Nov 2018.
  11. 11.
    Kaitin KI, ed. U.S. continues to lead new drug R&D, but Asia-Pacific is starting to rise. Tufts CSDD Impact Report (January/February 2019), vol. 21, number 1. Tufts University School of Medicine, Center for the Study of Drug Development, Boston, MA, USA, 2019.Google Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Tufts University School of MedicineBostonUSA
  2. 2.University of EdinburghEdinburghScotland, UK

Personalised recommendations